You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先瑞達醫療-B(06669.HK)中期經調整淨利升120%至3797萬元 研發成本同比增327.9%
格隆匯 08-30 22:56

格隆匯8月30日丨先瑞達醫療-B(06669.HK)發佈公吿,截至2021年6月30日止6個月,實現收益人民幣1.402億元,同比增長106.0%;毛利人民幣1.237億元,同比增長118.6%;期內經調整溢利淨額人民幣3796.6萬元,同比增長120.0%。

報吿期間,集團收益增加主要由於(i)使用集團的醫療器械進行的手術數量增加,(ii)自2021年1月起在中國推出的新核心產品AcoArt TulipTM & LitosTM,以及(iii)COVID-19疫情防控常態化使患者能夠正常就醫。值得注意的是,與截至2020年6月30日止六個月相比,使用集團的醫療器械進行的手術數量大幅增加。DCB銷售收益於截至2021年 6月30日止六個月佔集團總收益的98.6%,而於截至2020年6月30日止六個月佔98.0%。

集團截至2021年6月30日止六個月的研發成本為人民幣6140萬元,較截至2020年6月30日止六個月的人民幣1430萬元增加327.9%。該增加主要由於(i)於2020年5月27日收購的深圳研發中心的研發開支自2020年5月27日至2020年6月30日以及截至2021年6月30日止六個月的業務收購併入集團綜合財務報表,(ii)員工成本增加,(iii)2021年的以股份為基礎的報酬開支,以及(iv)加大投入正在進行的研發項目。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account